Gyre Therapeutics, Inc. Proceeds from Sale of Productive Assets
Gyre Therapeutics, Inc. (GYRE) reported Proceeds from Sale of Productive Assets of $13.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2026-08-07
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2026-06-30 was $7.00K, a 61.11% decline year-over-year.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2026-03-31 was $6.00K, a 500.00% increase year-over-year.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2025-12-31 was $11.00K, a 92.03% decline year-over-year.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for the quarter ending 2025-09-30 was $0.00.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2025 was $30.00K, a 92.52% decline from fiscal 2024.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2024 was $401.00K, a 39.61% decline from fiscal 2023.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2023 was $664.00K.
- Gyre Therapeutics, Inc. proceeds from sale of productive assets for fiscal 2016 was $1.67M.
| Period end | Proceeds from Sale of Productive Assets 3 month | Proceeds from Sale of Productive Assets 6 month | Proceeds from Sale of Productive Assets 9 month | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $13.00K 10-Q · filed 2026-08-07 | $24.00K derived: sum of 3 quarters · filed 2026-08-07 | $24.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $6.00K 10-Q · filed 2026-05-08 | $17.00K derived: sum of 2 quarters · filed 2026-05-08 | $17.00K derived: sum of 3 quarters · filed 2026-05-08 | $35.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $11.00K derived: sum of 2 quarters · filed 2026-03-13 | $29.00K derived: sum of 3 quarters · filed 2026-08-07 | $30.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $18.00K derived: sum of 2 quarters · filed 2026-08-07 | $19.00K 10-Q · filed 2025-11-07 | $157.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $19.00K 10-Q · filed 2026-08-07 | $157.00K derived: sum of 3 quarters · filed 2026-08-07 | $152.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-08 | $139.00K derived: sum of 2 quarters · filed 2026-05-08 | $134.00K derived: sum of 3 quarters · filed 2026-05-08 | $352.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $133.00K derived: sum of 2 quarters · filed 2026-03-13 | $351.00K derived: sum of 3 quarters · filed 2026-03-13 | $401.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $213.00K derived: sum of 2 quarters · filed 2025-11-07 | $263.00K 10-Q · filed 2025-11-07 | $430.00K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $218.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $268.00K 10-Q · filed 2025-08-11 | $435.00K derived: sum of 3 quarters · filed 2025-08-11 | $798.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $50.00K 10-Q · filed 2025-05-09 | $217.00K derived: sum of 2 quarters · filed 2025-05-09 | $580.00K derived: sum of 3 quarters · filed 2025-05-09 | |
| 2023-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $530.00K derived: sum of 2 quarters · filed 2025-03-17 | $664.00K 10-K · filed 2025-03-17 | |
| 2023-09-30 | $363.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $497.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $134.00K 10-Q · filed 2024-08-13 | |||
| 2016-12-31 | $1.67M 10-K · filed 2018-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |